دورية أكاديمية
أعرض في EDS

Predicting cognitive decline: Which is more useful, baseline amyloid levels or longitudinal change?

التفاصيل البيبلوغرافية
العنوان: Predicting cognitive decline: Which is more useful, baseline amyloid levels or longitudinal change?
المؤلفون: Chen G; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., McKay NS; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Gordon BA; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Liu J; Department of Surgery, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Joseph-Mathurin N; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Schindler SE; Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Hassenstab J; Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Aschenbrenner AJ; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Department of Neurology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Wang Q; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Schultz SA; Department of Neurology Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Su Y; Banner Alzheimer's Institute, Phoenix, AZ, USA., LaMontagne PJ; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Keefe SJ; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Massoumzadeh P; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Cruchaga C; Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Xiong C; Divison of Biostatistics, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Morris JC; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University in St. Louis School of Medicine, St. Louis, MO, USA., Benzinger TLS; Departments of Radiology, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Knight Alzheimer's Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA; Hope Center for Neurological Disorders, Washington University in St. Louis School of Medicine, St. Louis, MO, USA. Electronic address: benzingert@wustl.edu.
المصدر: NeuroImage. Clinical [Neuroimage Clin] 2024; Vol. 41, pp. 103551. Date of Electronic Publication: 2023 Dec 15.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101597070 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-1582 (Electronic) Linking ISSN: 22131582 NLM ISO Abbreviation: Neuroimage Clin Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier
مواضيع طبية MeSH: Alzheimer Disease*/diagnostic imaging , Cognitive Dysfunction*/diagnostic imaging, Humans ; Cross-Sectional Studies ; Amyloid beta-Peptides/metabolism ; Amyloid/metabolism ; Brain/diagnostic imaging ; Brain/metabolism ; Biomarkers ; Positron-Emission Tomography/methods ; Longitudinal Studies
مستخلص: The use of biomarkers for the early detection of Alzheimer's disease (AD) is crucial for developing potential therapeutic treatments. Positron Emission Tomography (PET) is a well-established tool used to detect β-amyloid (Aβ) plaques in the brain. Previous studies have shown that cross-sectional biomarkers can predict cognitive decline (Schindler et al.,2021). However, it is still unclear whether longitudinal Aβ-PET may have additional value for predicting time to cognitive impairment in AD. The current study aims to evaluate the ability of baseline- versus longitudinal rate of change in- 11 C-Pittsburgh compound B (PiB) Aβ-PET to predict cognitive decline. A cohort of 153 participants who previously underwent PiB-PET scans and comprehensive clinical assessments were used in this study. Our analyses revealed that baseline Aβ is significantly associated with the rate of change in cognitive composite scores, with cognition declining more rapidly when baseline PiB Aβ levels were higher. In contrast, no signification association was identified between the rate of change in PiB-PET Aβ and cognitive decline. Additionally, the ability of the rate of change in the PiB-PET measures to predict cognitive decline was significantly influenced by APOE ε4 carrier status. These results suggest that a single PiB-PET scan is sufficient to predict cognitive decline and that longitudinal measures of Aβ accumulation do not improve the prediction of cognitive decline once someone is amyloid positive.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Benzinger has held investigator-initiated research funding from the NIH, the Alzheimer’s Association, the Barnes-Jewish Hospital Foundation, Siemens Healthiness and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Dr. Benzinger participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Jansen, and Roche. Dr. Benzinger performs paid and unpaid consulting for Biogen, Eli Lilly, Eisai, Roche and Siemens. SES is analyzing biomarker data provided by C2N Diagnostics to Washington University.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
معلومات مُعتمدة: R01 AG043434 United States AG NIA NIH HHS; P01 AG003991 United States AG NIA NIH HHS; R01 EB009352 United States EB NIBIB NIH HHS; UL1 TR000448 United States TR NCATS NIH HHS; UL1 TR002345 United States TR NCATS NIH HHS; P01 AG026276 United States AG NIA NIH HHS; P30 AG072980 United States AG NIA NIH HHS; K01 AG080123 United States AG NIA NIH HHS; S10 RR022984 United States RR NCRR NIH HHS
فهرسة مساهمة: Keywords: Alzheimer’s disease; Amyloid; Cognition; Longitudinal study; PET
المشرفين على المادة: 0 (Amyloid beta-Peptides)
0 (Amyloid)
0 (Biomarkers)
تواريخ الأحداث: Date Created: 20231227 Date Completed: 20240318 Latest Revision: 20240427
رمز التحديث: 20240427
مُعرف محوري في PubMed: PMC10788301
DOI: 10.1016/j.nicl.2023.103551
PMID: 38150745
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-1582
DOI:10.1016/j.nicl.2023.103551